Ovid Therapeutics Stock Price, News & Analysis (NASDAQ:OVID)

$7.03 -0.01 (-0.14 %)
(As of 02/21/2018 04:00 PM ET)
Previous Close$7.03
Today's Range$6.90 - $7.66
52-Week Range$5.28 - $15.93
Volume106,200 shs
Average Volume70,706 shs
Market Capitalization$173.21 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics logoOvid Therapeutics Inc. (Ovid) is a biopharmaceutical company. The Company is engaged in developing medicines for patients and families living with rare neurological disorders. Its lead drug candidate is OV101. The Company’s second lead drug candidate is OV935. OV101 (gaboxadol) is a delta-selective GABAA receptor agonist. Ovid is developing OV101 for use in both Angelman syndrome and Fragile X syndrome to potentially restore tonic inhibition and relieve several of the symptoms of these disorders. Ovid has initiated the Phase II STARS trial of OV101 in adults with Angelman syndrome and a Phase I trial in adolescents with Angelman syndrome or Fragile X syndrome. Ovid is also developing OV935 in collaboration with Takeda Pharmaceutical Company Limited for the treatment of rare epileptic encephalopathies.

Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OVID
CUSIPN/A
Phone646-661-7661

Debt

Debt-to-Equity RatioN/A
Current Ratio21.06%
Quick Ratio21.06%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net Income$-22,410,000.00
Net MarginsN/A
Return on Equity-86.05%
Return on Assets-80.34%

Miscellaneous

Employees31
Outstanding Shares24,600,000

Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc (NASDAQ:OVID) posted its quarterly earnings data on Thursday, November, 9th. The company reported ($0.38) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.16. View Ovid Therapeutics' Earnings History.

When will Ovid Therapeutics make its next earnings announcement?

Ovid Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for Ovid Therapeutics.

Where is Ovid Therapeutics' stock going? Where will Ovid Therapeutics' stock price be in 2018?

4 analysts have issued 1 year target prices for Ovid Therapeutics' shares. Their predictions range from $21.00 to $26.00. On average, they expect Ovid Therapeutics' stock price to reach $23.50 in the next year. View Analyst Ratings for Ovid Therapeutics.

Who are some of Ovid Therapeutics' key competitors?

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the folowing people:

  • Jeremy Max Levin, Chairman of the Board, Chief Executive Officer (Age 65)
  • Matthew During M.D., President, Chief Scientific Officer, Director (Age 60)
  • Yaron Werber M.D., Chief Business and Financial Officer, Secretary (Age 45)
  • Dirk Haasner Ph.D., Senior Vice President - Global Regulatory Affairs (Age 52)
  • Timothy G. Daly, Vice President - Finance, Corporate Controller (Age 45)
  • Amit Rakhit M.D., Chief Medical and Portfolio Management Officer (Age 47)
  • Bart Friedman, Lead Independent Director (Age 72)
  • Barbara G. Duncan, Director (Age 52)
  • Karen Bernstein Ph.D., Independent Director (Age 64)
  • Douglas E. Williams Ph.D., Independent Director (Age 59)

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an initial public offering (IPO) on Friday, May 5th 2017. The company issued 5,000,000 shares at $15.00-$17.00 per share. Citigroup and Cowen and Company served as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

Who owns Ovid Therapeutics stock?

Ovid Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (4.32%), Jennison Associates LLC (2.35%), Tekla Capital Management LLC (2.18%), Redmile Group LLC (1.27%), Sphera Funds Management LTD. (0.73%) and Schwab Charles Investment Management Inc. (0.08%). View Institutional Ownership Trends for Ovid Therapeutics.

Who sold Ovid Therapeutics stock? Who is selling Ovid Therapeutics stock?

Ovid Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Sphera Funds Management LTD., Jennison Associates LLC and BlackRock Inc.. View Insider Buying and Selling for Ovid Therapeutics.

Who bought Ovid Therapeutics stock? Who is buying Ovid Therapeutics stock?

Ovid Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Tekla Capital Management LLC, Granite Point Capital Management L.P., Spark Investment Management LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Ovid Therapeutics.

How do I buy Ovid Therapeutics stock?

Shares of Ovid Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ovid Therapeutics' stock price today?

One share of Ovid Therapeutics stock can currently be purchased for approximately $7.03.

How big of a company is Ovid Therapeutics?

Ovid Therapeutics has a market capitalization of $173.21 million. Ovid Therapeutics employs 31 workers across the globe.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 BROADWAY SUITE 15044, NEW YORK NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]


MarketBeat Community Rating for Ovid Therapeutics (OVID)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  104 (Vote Outperform)
Underperform Votes:  72 (Vote Underperform)
Total Votes:  176
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ovid Therapeutics (NASDAQ:OVID) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $23.50$23.50$23.50$23.50
Price Target Upside: 62.29% upside62.29% upside62.29% upside62.29% upside

Ovid Therapeutics (NASDAQ:OVID) Consensus Price Target History

Price Target History for Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics (NASDAQ:OVID) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/30/2017CitigroupInitiated CoverageBuy -> Buy$21.00HighView Rating Details
5/30/2017William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
5/30/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$26.00HighView Rating Details
5/30/2017CowenInitiated CoverageOutperformHighView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Ovid Therapeutics (NASDAQ:OVID) Earnings History and Estimates Chart

Earnings by Quarter for Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics (NASDAQ OVID) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/22/2018        
11/9/2017Q3 2017($0.54)($0.38)ViewN/AView Earnings Details
8/10/2017Q2 2017($0.48)($0.57)ViewN/AView Earnings Details
6/13/2017Q1 2017($0.87)($3.48)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ovid Therapeutics (NASDAQ:OVID) Earnings Estimates

2018 EPS Consensus Estimate: ($2.19)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.48)($0.48)($0.48)
Q2 20181($0.54)($0.54)($0.54)
Q3 20181($0.59)($0.59)($0.59)
Q4 20181($0.58)($0.58)($0.58)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Ovid Therapeutics (NASDAQ:OVID)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ovid Therapeutics (NASDAQ OVID) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 27.52%
Insider Trades by Quarter for Ovid Therapeutics (NASDAQ:OVID)
Institutional Ownership by Quarter for Ovid Therapeutics (NASDAQ:OVID)

Ovid Therapeutics (NASDAQ OVID) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/25/2017Jeremy M LevinCEOBuy15,334$7.15$109,638.104,601,529View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ovid Therapeutics (NASDAQ OVID) News Headlines

Source:
DateHeadline
Ovid Therapeutics Inc (OVID) Given Average Rating of "Buy" by AnalystsOvid Therapeutics Inc (OVID) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - February 19 at 1:30 AM
Ovid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare ConferenceOvid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference
finance.yahoo.com - February 15 at 4:25 PM
Ovid Therapeutics (OVID) Upgraded to "Hold" at ValuEngineOvid Therapeutics (OVID) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - February 4 at 6:06 PM
Ovid Therapeutics Inc (OVID) Receives Consensus Recommendation of "Buy" from AnalystsOvid Therapeutics Inc (OVID) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - January 25 at 1:30 AM
Ovid Therapeutics (OVID) and Its Rivals Head to Head ContrastOvid Therapeutics (OVID) and Its Rivals Head to Head Contrast
www.americanbankingnews.com - January 24 at 5:14 AM
Ovid Therapeutics Inc (OVID) Expected to Announce Earnings of -$0.42 Per ShareOvid Therapeutics Inc (OVID) Expected to Announce Earnings of -$0.42 Per Share
www.americanbankingnews.com - January 20 at 3:28 PM
Ovid Therapeutics (OVID) Lifted to "Buy" at Zacks Investment ResearchOvid Therapeutics (OVID) Lifted to "Buy" at Zacks Investment Research
www.americanbankingnews.com - January 14 at 12:40 PM
Critical Contrast: Ovid Therapeutics (OVID) versus Its RivalsCritical Contrast: Ovid Therapeutics (OVID) versus Its Rivals
www.americanbankingnews.com - January 11 at 9:48 PM
Ovid Therapeutics (OVID) versus The Competition Financial ContrastOvid Therapeutics (OVID) versus The Competition Financial Contrast
www.americanbankingnews.com - January 10 at 11:14 PM
Critical Survey: Ovid Therapeutics (OVID) and The CompetitionCritical Survey: Ovid Therapeutics (OVID) and The Competition
www.americanbankingnews.com - January 9 at 7:08 PM
Ovid Therapeutics (OVID) Lifted to Sell at ValuEngineOvid Therapeutics (OVID) Lifted to Sell at ValuEngine
www.americanbankingnews.com - January 1 at 1:36 PM
Ovid Therapeutics Inc (OVID) Receives Average Rating of "Buy" from BrokeragesOvid Therapeutics Inc (OVID) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - December 31 at 11:34 PM
 Analysts Set $21.00 Price Target for Ovid Therapeutics Inc (OVID) Analysts Set $21.00 Price Target for Ovid Therapeutics Inc (OVID)
www.americanbankingnews.com - December 28 at 1:38 AM
BRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut SyndromeBRIEF-Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation By U.S. FDA For Treatment Of Lennox-Gastaut Syndrome
www.reuters.com - December 21 at 9:00 AM
Ovid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut SyndromeOvid Therapeutics Announces TAK-935/OV935 Granted Orphan Drug Designation by U.S. FDA for Treatment of Lennox-Gastaut Syndrome
finance.yahoo.com - December 20 at 9:00 AM
Ovid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman SyndromeOvid Therapeutics Announces OV101 Granted Fast Track Designation by U.S. FDA for Treatment of Angelman Syndrome
finance.yahoo.com - December 19 at 9:00 AM
Zacks: Ovid Therapeutics Inc (OVID) Receives Average Rating of "Strong Buy" from AnalystsZacks: Ovid Therapeutics Inc (OVID) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - December 13 at 7:54 AM
 Ovid Therapeutics Inc (OVID) Receives Average Recommendation of "Strong Buy" from Brokerages Ovid Therapeutics Inc (OVID) Receives Average Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - December 9 at 3:36 AM
Ovid Therapeutics (OVID) TAK-935/OV935 Receives Orphan Drug Designation from FDA for Treatment of Dravet SyndromeOvid Therapeutics' (OVID) TAK-935/OV935 Receives Orphan Drug Designation from FDA for Treatment of Dravet Syndrome
www.streetinsider.com - December 5 at 5:42 PM
BRIEF-Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet SyndromeBRIEF-Ovid Therapeutics Announces TAK-935/Ov935 Has Received Orphan Drug Designation From U.S. FDA For Treatment Of Dravet Syndrome
www.reuters.com - December 5 at 9:24 AM
Ovid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet SyndromeOvid Therapeutics Announces TAK-935/OV935 Has Received Orphan Drug Designation from U.S. FDA for Treatment of Dravet Syndrome
finance.yahoo.com - December 5 at 9:24 AM
Ovid Therapeutics Presents New Data Demonstrating...Ovid Therapeutics Presents New Data Demonstrating...
www.benzinga.com - December 4 at 5:45 PM
Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel TreatmentOvid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment
www.nasdaq.com - December 3 at 5:47 PM
Ovid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual MeetingOvid Therapeutics Presents New Data Demonstrating Potential of TAK-935/OV935 as a Novel Treatment for Developmental and Epileptic Encephalopathies at the American Epilepsy Society (AES) Annual Meeting
finance.yahoo.com - December 3 at 5:47 PM
Ovid Therapeutics Inc Forecasted to Post Q1 2018 Earnings of ($0.48) Per Share (OVID)Ovid Therapeutics Inc Forecasted to Post Q1 2018 Earnings of ($0.48) Per Share (OVID)
www.americanbankingnews.com - December 1 at 5:08 PM
BRIEF-Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent PatientsBRIEF-Ovid Therapeutics Announces OV101 Shows Comparable Pk Profile In Phase 1 Study Of Adolescent Patients
www.reuters.com - November 28 at 5:45 PM
Ovid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include AdolescentsOvid Therapeutics Announces OV101 Shows Comparable PK Profile in Phase 1 Study of Adolescent Patients and Amends Phase 2 STARS Clinical Trial Protocol to Include Adolescents
finance.yahoo.com - November 28 at 5:45 PM
Zacks: Analysts Set $21.00 Price Target for Ovid Therapeutc (OVID)Zacks: Analysts Set $21.00 Price Target for Ovid Therapeutc (OVID)
www.americanbankingnews.com - November 24 at 5:34 AM
Ovid Therapeutics: Is There More Upside After A 75% Gain In 3 Weeks?Ovid Therapeutics: Is There More Upside After A 75% Gain In 3 Weeks?
seekingalpha.com - November 23 at 5:35 PM
Ovid Therapeutics to Participate in Two Upcoming Investor ConferencesOvid Therapeutics to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - November 21 at 9:05 AM
Ovid Therapeutc (OVID) Raised to Buy at Zacks Investment ResearchOvid Therapeutc (OVID) Raised to Buy at Zacks Investment Research
www.americanbankingnews.com - November 16 at 6:32 AM
Ovid Therapeutc (OVID) Releases Quarterly  Earnings Results, Beats Expectations By $0.16 EPSOvid Therapeutc (OVID) Releases Quarterly Earnings Results, Beats Expectations By $0.16 EPS
www.americanbankingnews.com - November 10 at 2:56 PM
BRIEF-Ovid Therapeutics Q3 loss per share $0.38BRIEF-Ovid Therapeutics Q3 loss per share $0.38
www.reuters.com - November 10 at 9:32 AM
Ovid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate ProgressOvid Therapeutics Reports Third Quarter 2017 Financial Results and Corporate Progress
finance.yahoo.com - November 9 at 8:31 PM
Ovid Therapeutics to Participate at the Stifel 2017 Healthcare ConferenceOvid Therapeutics to Participate at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 9 at 10:48 AM
 Ovid Therapeutc (OVID) Given Consensus Recommendation of "Strong Buy" by Analysts Ovid Therapeutc (OVID) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - November 7 at 10:59 AM
Reviewing Seres Therapeutics (MCRB) & Ovid Therapeutc (OVID)Reviewing Seres Therapeutics (MCRB) & Ovid Therapeutc (OVID)
www.americanbankingnews.com - November 2 at 9:38 PM
Ovid Therapeutics: Takeda Partnership And Near Term Catalysts Make This A BuyOvid Therapeutics: Takeda Partnership And Near Term Catalysts Make This A Buy
seekingalpha.com - November 1 at 7:20 AM
 Brokerages Set $21.00 Target Price for Ovid Therapeutc (OVID) Brokerages Set $21.00 Target Price for Ovid Therapeutc (OVID)
www.americanbankingnews.com - October 23 at 10:58 AM
Ovid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome ModelOvid Therapeutics Announces Positive Preclinical OV101 Data Demonstrating Behavioral Improvements in Fragile X Syndrome Model
finance.yahoo.com - October 17 at 5:53 AM
Ovid Therapeutics (OVID) Confirms FDA Orphan Drug Designation for OV101 for Treatment of Fragile X SyndromeOvid Therapeutics (OVID) Confirms FDA Orphan Drug Designation for OV101 for Treatment of Fragile X Syndrome
www.streetinsider.com - October 11 at 6:20 AM
Ovid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X SyndromeOvid Therapeutics Receives Orphan Drug Designation from the U.S. FDA for OV101 for Treatment of Fragile X Syndrome
finance.yahoo.com - October 11 at 6:19 AM
 Ovid Therapeutc (OVID) Given $21.00 Average Target Price by Analysts Ovid Therapeutc (OVID) Given $21.00 Average Target Price by Analysts
www.americanbankingnews.com - October 7 at 6:28 PM
Ovid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders WorkshopOvid Therapeutics to Present Preclinical Data Demonstrating OV101 Normalizes Behavioral Abnormalities at the 18th International Fragile X and Related Neurodevelopmental Disorders Workshop
finance.yahoo.com - October 5 at 7:38 PM
Zacks: Ovid Therapeutc (OVID) Given $21.00 Consensus Target Price by AnalystsZacks: Ovid Therapeutc (OVID) Given $21.00 Consensus Target Price by Analysts
www.americanbankingnews.com - October 4 at 10:24 PM
 Brokerages Set $21.00 Price Target for Ovid Therapeutc (OVID) Brokerages Set $21.00 Price Target for Ovid Therapeutc (OVID)
www.americanbankingnews.com - September 25 at 12:34 PM
 Ovid Therapeutc (OVID) Given $21.00 Consensus Target Price by Analysts Ovid Therapeutc (OVID) Given $21.00 Consensus Target Price by Analysts
www.americanbankingnews.com - September 19 at 2:38 AM
Ovid Therapeutics Appoints Ana C. Ward as Senior Vice President and General CounselOvid Therapeutics Appoints Ana C. Ward as Senior Vice President and General Counsel
finance.yahoo.com - September 7 at 7:21 AM
Ovid Therapeutc (OVID) CEO Jeremy M. Levin Buys 15,334 SharesOvid Therapeutc (OVID) CEO Jeremy M. Levin Buys 15,334 Shares
www.americanbankingnews.com - August 28 at 7:42 PM
Ovid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare EpilepsiesOvid Therapeutics Announces First Patient Randomized in Phase 1b/2a Clinical Trial of TAK-935/OV935 in Adults with Rare Epilepsies
finance.yahoo.com - August 22 at 2:51 AM

SEC Filings

Ovid Therapeutics (NASDAQ:OVID) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ovid Therapeutics (NASDAQ:OVID) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ovid Therapeutics (NASDAQ OVID) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.